top of page

Mature Tumoroid Resistance Profiling™

A Translational Pilot Program for Human-Relevant Drug Response

NAMina integrates advanced biological systems, functional profiling, and

multi-omics analytics into a unified translational decision framework.

1775669991650.jpg

Most preclinical models fail not because they are incorrect, but because they are incomplete. They do not capture how tumors evolve under treatment.

Overview

Standard preclinical models often overestimate drug efficacy because they fail to capture the adaptive resistance observed in patients. At NAMina Bio, we leverage LifeGel-based mature tumoroid systems to reveal clinically relevant resistance dynamics that emerge over time in advanced 3D tumor models.

​

This pilot program quantifies how drug response evolves under physiologically relevant conditions, revealing signals that standard models miss.

Why Standard Models Fail and What Changes Here

  • Time-dependent resistance modeling
    Tumoroids cultured beyond early-stage 3D reveal adaptive drug tolerance not visible in standard assays

  • GR-based quantitative analysis
    Growth Rate (GR) metrics provide unbiased, clinically relevant response measurements

  • Human-relevant architecture
    Matured 3D tumor systems better reflect in vivo microenvironmental constraints

Descriptive comparison of 5-fluorouracil sensitivity across PDAC model systems relative to clinical exposure. IC₅₀ values for 5-fluorouracil measured in 2D cultures, organoids, and extended 3D tumoroid models are displayed relative to reported peak plasma concentrations (Cmax) observed in patients receiving systemic 5-FU therapy. The dashed line indicates the reported clinical plasma Cmax (~426 µM). This plot is intended as a visual comparison of representative IC₅₀ values across model systems rather than a statistical analysis. Extended 3D tumoroids exhibit IC₅₀ values approaching clinically relevant exposure levels, whereas conventional 2D cultures substantially underestimate drug resistance. 

doi: https://doi.org/10.64898/2026.04.04.716464

LifeGel (Real Research) is a physiologically relevant hydrogel matrix that supports the development of structurally and functionally mature 3D tumor systems.

MiaPACA-Mature Tumoroid.png
Figure 6-Mature Tumoroid.png

Experimental Validation

These data illustrate how extended 3D maturation shifts drug response toward clinically relevant exposure levels.

Time-in-3D pre-conditioning reduces drug sensitivity in MiaPaCa-2 spheroids. Growth-rate–normalized dose–response (GR) curves for MiaPaCa-2 spheroids pre-cultured in an ECM-containing 3D hydrogel for 4, 7, 11 days, then treated for 72 h with (upper panels) gemcitabine (GEM, left) and 5-fluorouracil (5FU, right) or (bottom panels) SN38 (left) and paclitaxel (PAC, right). Points show mean ± SEM.; horizontal black line marks GR = 0 (cytostatic threshold). Axes: x, log10 (drug) (µM); y, normalized GR.

doi: https://doi.org/10.64898/2026.04.04.716464

Functional drug-response shifts

Summary of ΔGR_AOC values (3D Day 11 − 2D Day 4; unitless) for each drug–cell-line pair (MiaPaCa-2, PANC-1, CFPAC-1). Boxes indicate the magnitude and significance of activity changes relative to 2D culture (pink, reduced sensitivity in 3D; green, increased sensitivity in 3D; *P<0.05, **P<0.01).

doi: https://doi.org/10.64898/2026.04.04.716464

Mature Tumoroid Resistance Profiling™ — Pilot Program

This pilot program translates the NAMina framework into a focused, execution-ready study designed to reveal clinically relevant drug response dynamics.

​

Pilot Scope

  • Tumoroid generation using LifeGel-based systems and extended maturation (≥ 8 days)

  • Drug treatment across defined concentration ranges

  • Comparative analysis:

    • 2D vs early 3D vs mature tumoroids

  • GR-based response profiling (GR50, cytostatic vs cytotoxic effects)

  • Delivery of a structured translational report

​

Advanced Functional Capabilities (Optional Expansion)

  • For deeper insight, the pilot can be extended to include:

  • Longitudinal studies and recovery assays

  • Repeated dose and combination strategies

  • Target engagement and time-dependent response analysis

  • Patient-derived 3D tumor systems

  • Dose optimization to support translational decisions

​

​Designed to directly impact preclinical decision-making:

​

Key Outputs

  • Identification of hidden resistance phenotypes

  • More realistic estimation of effective dose ranges

  • Early detection of false positives in preclinical pipelines

​

Timeline & Format

  • Duration: 4–6 weeks

  • Format: Pilot engagement

  • Output: Data package + interpretive report

The NAMina framework integrates structure, biology, and analytics into a unified translational system:

Mature Tumoroid-NAMina platform slide_Wix page.png

Call to Action

Test your compounds in a system that reflects real tumour behaviour.
Identify resistance early. Make better decisions faster.

​

Technology Foundation

​

The NAMina platform is built on a modular architecture integrating biological, physical, and analytical layers.

 

Within this system, LifeGel-based systems represent the structural and microenvironmental foundation, enabling the controlled maturation of 3D tumour systems.

 

This layer is critical to:

​

  • Unlock time-dependent tumor adaptation

  • Support emergence of resistance mechanisms

  • Enable accurate downstream quantitative analysis (GR metrics)

​

Together, this creates a human-relevant testing environment where drug response reflects biological reality rather than simplified model assumptions.

Who This Is For

​

  • Biotech companies optimising lead compounds

  • Teams facing inconsistent preclinical results

  • Programs preparing for IND-enabling studies

bottom of page